Dr Peter Hall is an academic Medical Oncologist with a research interest in Health Economics and Health Technology Assessment in Cancer. He treats patients with breast cancer within the NHS at the Edinburgh Cancer Centre.
The focus of his research is on the development of improved methods for efficient research design, cost-effectiveness analysis and the measurement of clinical and socioeconomic outcomes using data obtained from clinical trials and routinely collected within health systems.
He has contributed to the design of a series of pragmatic clinical trials in the UK that aim to address questions that are important to real-world patients with cancer treated by the NHS. Examples include the PETNECK, 321GO, GO2, PERSEPHONE, OPTIMA and MAMMO-50 trials.
He graduated from the University of Edinburgh Medical School in 2003, undertaking general medical training in Fife and Dundee. He commenced specialist training in Medical Oncology with the Yorkshire Deanery in 2006. He undertook at NICE scholarship in 2007. He completed a PhD in Health Economics and Clinical Trial design at the University of Leeds in 2012. In 2014 he took up his current position in Edinburgh.
He leads the Health Economics Group within the University of Edinburgh Clinical Trials Unit. He has been a NICE Appraisal Committee member since 2017. He is a Visiting Associate Professor of Health Economics at the Academic Unit of Health Economics, University of Leeds .